Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)

October 14, 2025 updated by: Wilson Tang, The Cleveland Clinic

Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)

The investigators are interested in learning more about choline, a nutrient required by the body. The body does make some choline, but it does not make enough to support health and the rest must be acquired through diet. Eggs, and especially egg yolks, are a major dietary source of choline. Choline can also be given as a dietary supplement. Ingestion of choline supplements has been linked to an increased concentration of a compound called TMAO (trimethylamine N-oxide). Elevated TMAO levels have been linked to higher heart disease risk. With this study, the investigators hope to learn whether there is a difference in the way your body responds to the ingestion of a choline supplement versus the choline found within eggs.

Study Overview

Detailed Description

The principal goal for the study is to examine whether there is a difference between the ingestion of choline through supplements versus choline found within eggs on plasma TMAO levels. The investigators have previously shown that dietary intake of trimethylamines, including the choline group of phosphatidylcholine (PC), is mechanistically linked to cardiovascular disease risk and that the metabolism of these trimethylamine nutrients in humans is modulated by the intestinal microbes (gut microbes). Additionally, extensive animal studies link an essential role of gut microbiota to the metabolism of choline and the production of metabolites that promote / accelerate atherosclerotic processes. The investigators have also recently shown a 10-fold increase in plasma TMAO levels following supplementation with choline bitartrate supplements. However, another pilot study by a collaborator (unpublished) did not show the same increase in plasma TMAO levels following the ingestion of whole eggs, a major dietary source of choline. Therefore, with this study the investigators wish to examine the differences, if any, between the ingestion of an equivalent mass of total choline in the free form (as bitartrate salt) as a supplement vs. within whole eggs.

Eggs, and specifically the egg yolk, contain a large amount of total choline. However, egg white contains potential anti-microbial peptides that could influence gut microbial composition and function, and therefore impact conversion of choline into TMA and TMAO observed in subjects. Therefore, the investigators hypothesize that the consumption of whole eggs (hardboiled) will not elevate plasma TMAO levels to the same extent as a comparable amount of total choline ingested in capsule form as the choline bitartrate salt. The investigators further hypothesize that the consumption of egg white with choline bitartrate tablets may result in less of a rise in TMAO levels than ingestion of the choline bitartrate supplement alone.

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Men and women age 18 years or above.
  • Willing to remain on aspirin or stay off aspirin or aspirin products for 1 week prior to starting the study and throughout the study period.
  • Able to provide informed consent and comply with study protocol.
  • Able to be off all other supplements during the study period.

Exclusion Criteria:

  • Significant chronic illness.
  • Active infection or received antibiotics within 1 month of study enrollment.
  • Use of over-the-counter probiotic within the past month
  • Chronic gastrointestinal disorders, such as ulcerative colitis or Crohn's disease.
  • Allergy to eggs or lactose.
  • Having undergone bariatric procedures or surgeries such as gastric banding or bypass.
  • Pregnancy.
  • Any condition that, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial or cause inability to comply with the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Whole Hardboiled Eggs
Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
Obtained from a commercial source.
Experimental: Choline Bitartrate Tablets
Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
500mg choline bitartrate tablets
Experimental: Hardboiled Eggs + Choline Bitartrate Tablets
Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
Obtained from a commercial source.
500mg choline bitartrate tablets
Experimental: Egg Whites + Choline Bitartrate Tablets
Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
500mg choline bitartrate tablets
Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
Experimental: Phosphatidylcholine Capsules
Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
420 mg phosphatidylcholine capsules obtained from a commercial source.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO), a Choline Metabolite
Time Frame: Baseline, 28 days
Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry.
Baseline, 28 days
Changes in Platelet Function With Increased Choline Intake
Time Frame: Baseline, Day 28
The activation and functioning of platelets within a single subject will be compared before and after increased choline intake.
Baseline, Day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Levels of Fasting Trimethylamine-N-oxide (TMAO) in 24-hour Urine Collections
Time Frame: Baseline, Day 28
Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques.
Baseline, Day 28
Changes in Plasma Levels of Fasting Choline
Time Frame: Baseline, Day 28
Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared.
Baseline, Day 28
Changes in Plasma Levels of Fasting Carnitine.
Time Frame: Baseline, Day 28
Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared.
Baseline, Day 28
Changes in Plasma Levels of Fasting Betaine.
Time Frame: Baseline, Day 28
Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared.
Baseline, Day 28
Changes in Lipid Profile, Total Cholesterol
Time Frame: Baseline, Day 28
Changes in total cholesterol levels between baseline and Day 28
Baseline, Day 28
Changes in Lipid Profile, HDL
Time Frame: Baseline, Day 28
Changes in measured HDL levels between baseline and Day 28
Baseline, Day 28
Changes in Lipid Profile, LDL
Time Frame: Baseline, Day 28
Changes in measured LDL levels between baseline and Day 28
Baseline, Day 28
Changes in Lipid Profile, Triglycerides
Time Frame: Baseline, Day 28
Changes in measured triglyceride levels between baseline and Day 28
Baseline, Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: W. H. Wilson Tang, MD, The Cleveland Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 2, 2016

Primary Completion (Actual)

April 10, 2018

Study Completion (Actual)

September 3, 2020

Study Registration Dates

First Submitted

January 19, 2017

First Submitted That Met QC Criteria

January 30, 2017

First Posted (Estimated)

February 1, 2017

Study Record Updates

Last Update Posted (Estimated)

November 4, 2025

Last Update Submitted That Met QC Criteria

October 14, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk Factor

Clinical Trials on Pre-cooked, pre-peeled whole hardboiled eggs

Subscribe